# pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer

> **NCT05799144** · PHASE2 · RECRUITING · sponsor: **Michael K. Gibson** · enrollment: 54 (estimated)

## Conditions studied

- Metastatic Oropharyngeal Carcinoma
- Recurrent Oropharyngeal Carcinoma

## Interventions

- **BIOLOGICAL:** DNA Vaccine
- **BIOLOGICAL:** Human Papillomavirus Tumor Antigen Vaccine
- **BIOLOGICAL:** Pembrolizumab
- **PROCEDURE:** Computed Tomography (CT)
- **PROCEDURE:** Magnetic Resonance Imaging (MRI)
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Biopsy

## Key facts

- **NCT ID:** NCT05799144
- **Lead sponsor:** Michael K. Gibson
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-16
- **Primary completion:** 2027-09-30
- **Final completion:** 2028-09-30
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2025-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05799144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05799144, "pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05799144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*